
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450 on:



Our File No. LOU02-016-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re	Application of:)
Cedri	c Francois)
Serial	No. 10/724,527)) Examiner To Be Assigned
Filing	Date: November 28, 2003)) Group Art Unit No. 1651
For	Compositions and Methods for Treating Transplants)))

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In accordance with the provisions of 37 C.F.R. § 1.56, Applicants request that citation and examination of the references identified on the attached PTO-1449 form, required copies of which are enclosed herewith in accordance with 37 C.F.R. §1.98, be made during the course of examination of the above-referenced application for United States Letters Patent.

Respectfully submitted,

Paul E. Rauch, Ph.D. Registration No. 38,591

Evan Law Group LLC 566 West Adams Suite 350 Chicago, Illinois 60661 (312) 876-1400

	A14	Franken, RI, F.W. Peter, G.L. Anderson, W.Z. Wang, P.M. Werker, D.A. Schuschke, M. Kon, and J.H. Barker. 1996. Anatomy of the feeding blood vessels of the cremaster muscle
		in the rat. Microsurgery. 17:402-408.
	A15	Green, D.R., and T.A. Ferguson. 2001. The role of Fas ligand in immune privilege.
	713	Nat. Rev. Mol. Cell Biol. 2:917-924.
	A16	Griffith, T.S., T. Brunner, S.M. Fletcher, D.R. Green, and T.A. Ferguson. 1995. Fas ligand-
	' ' '	induced apoptosis as a mechanism of immune privilege. Science. 270:1189-1192.
	A17	Haque, M.E., T.J. McIntosh, and B.R. Lentz. 2001. Influence of lipid composition on
		physical properties and peg-mediated fusion of curved and uncurved model membrane
		vesicles: "nature's own" fusogenic lipid bilayer. Biochemistry. 40:4340-4348
	A18	Helderman, J.H., and S. Goral. 2000. Transplantation for the millennium: attaining tolerance
		in our timethe Holy Grail. Semin. Nephrol. 20:83-86.
	A19	Hu, Q., C.R. Shew, M.B. Bally, and T.D. Madden. 2001. Programmable fusogenic vesicles
		for intracellular delivery of antisense oligodeoxynucleotides: enhanced cellular uptake and
		biological effects. Biochim. Biophys. Reta. 1514:1-13.
	A20	Ildstad, S.T., and D.H. Sachs. 1984. Reconstitution with syngeneic plus allogeneic or
		xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature.
		307:168-170.
	A21	Jahn, R. and Sudhof, T.C. 1999. Membrane fusion and exocytosis. Annu Rev Biochem
		68. 863-911.
	A22	Jones, J.W., S.A. Gruber, J.H. Barker, and W.C. Breidenbach. 2000. Successful hand
		transplantation. One-year follow-up. Louisville Hand Transplant Team. N. Engl. J. Med. 343:468-473
		Ju, S.T., D.J. Panka, H. Cui, R. Ettinger, M. el Khatib, D.H. Sherr, B.Z. Stanger, and A.
	A23	Marshak-Rothstein. 1995. Fas(CD95)/FasL interactions required for programmed cell death
		after T-cell activation. Nature. 373:444-448
	1004	Kabelitz, D., T. Pohl, and K. Pechhold. 1993. Activation-induced cell death (apoptosis) of
	A24	mature peripheral T lymphocytes. <i>Immunol.Today.</i> 14:338-339
	A25	Kang, S.M., D.B. Schneider, Z. Lin, D. Hanahan, D.A. Dichek, P.G. Stock, and S.
	A25	Baekkeskov. 1997. Fas ligand expression in islets of Langerhans does not confer immune
		privilege and instead targets them for rapid destruction. <i>Nat. Med.</i> 3:738-743.
	A26	Kann, B.R., D.W. Furnas, and C.W. Hewitt. 2000. Past, present, and future research in the
	1 120	field of composite tissue allotransplantation. <i>Microsurgery</i> . 20:393-399.
	A27	Kirk, A.D., L.C. Burkly, D.S. Batty, R.E. Baumgartner, J.D. Berning, K. Buchanan, J.H.
	' '-'	Fechner, Jr., R.L. Germond, R.L. Kampen, N.B. Patterson, S.J. Swanson, D.K. Tadaki, C.N.
		TenHoor, L. White, S.J. Knechtle, and D.M. Harlan. 1999. Treatment with humanized monoclonal antibody
		against CD 154 prevents acute renal allograft rejection in nonhuman
		primates. Nat. Med 5:686-693.
	A28	Kirk, A.D., D.A. Hale, R.B. Mannon, D.E. Kleiner, S.C. Hoffmann, R.L. Kampen, L.K.
		Cendales, D.K. Tadaki, D.M. Harlan, and S.J. Swanson. 2003. Results from a human renal
		allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody
		alemtuzumab (CAMPATH-1 H). Transplantation. 76:120-129.
	A29	Kirk, A.D., D.M. Harlan, N.N. Armstrong, T.A. Davis, Y. Dong, G.S. Gray, X. Hong, D.
		Thomas, J.H. Fechner, Jr., and S.J. Knechtle. 1997. CTLA4-lg and anti-CD40 ligand
		prevent renal allograft rejection in primates. Proc. Natl. Acad. Sci. U.S.A. 94:8789-8794.
	A30	Kishimoto, K., V.M. Dong, and M.H. Sayegh. 2000. The role of costimulatory molecules as
		targets for new immunosuppressives in transplantation. Curr. Opin. Urol. 10:57-62.
	A31	Krammer, P.H., J. Dhein, H. Walczak, I. Behrmann, S. Mariani, B. Matiba, M. Fath, P.T.
		Daniel, E. Knipping, M.O. Westendorp, and . 1994. The role of APO-1-mediated apoptosis
		in the immune system. Immunol. Rev. 142:175-191
	A32	Kuhl, et al., 1998. A neutron reflectivity study of polymer-modified phospholipid
		monolayers at the solid-solution interface: polyethylene glycol-lipids on silane-modified
		substrates. Biophys J. 75:2352-62.
1	A33	Lau, H.T., M. Yu, A. Fontana, and C.J. Stoeckert, Jr. 1996. Prevention of islet allograft
	l	rejection with engineered myoblasts expressing FasL in mice. Science. 273:109-112.

Form PTO-1449 (Rev. 8-88)	Attorney Docket No. LOU02-016-US	Serial No. 10/724,527
	Applicant: Cedric Francois	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Filing Date: November 28, 2003	1651

Examiner Initial*	OTHER ITEMS - NON PATENT LITERATURE DOCUMENTS Include, as applicable: Author, Title, Date, Publisher, Edition or Volume, Pertinent Pages	
IIIIIIII	A1	Adler, S.H., and L.A. Turka. 2002. Immunotherapy as a means to induce transplantation tolerance. <i>Curr. Opin. Immunol.</i> 14:660-665.
	A2	Ainscow, E.K. and Brand, M.D. 1999. Top-down control analysis of ATP turnover, glycolysis and oxidative phosphorylation in rat hepatocytes. Eur. J. Biochem. 263. 671-685
	A3	Arai, H., S.Y. Chan, D.K. Bishop, and G.J. Nabel. 1997. Inhibition of the alloantibody response by CD95 ligand. <i>Nat. Med</i> 3:843-848.
	A4	Askenasy, N., E.S. Yolcu, Z. Wang, and H. Shirwan. 2003. Display of Fas ligand protein on cardiac vasculature as a novel means of regulating allograft rejection. <i>Circulation</i> . 107:1525-1531.
	A5	Avila-Sakar, A.J., and W. Chits. 1996. Visualization of beta-sheets and side-chain clusters in two-dimensional periodic arrays of streptavidin on phospholipid monolayers by electron crystallography. <i>Biophys J.</i> 70:57-68.
	A6	Bell, E.B., D. Rejali, E.H. Whitby, S.M. Sparshott, and C.P. Yang. 1990. Allograft rejection in athymic nude rats by transferred T cell subsets. IL The response of naive CD4+ and CD8+ thoracic duct lymphocytes to an isolated MHC class I disparity, <i>Transplantation</i> . 50:690-696.
	A7	Bellgrau, D., D. Gold, H. Selawry, J. Moore, A. Franzusoff, and R.C. Duke. 1995. A role for CD95 ligand in preventing graft rejection. <i>Nature</i> . 377:630-632.
	A8	Borisenko, G.G., T. Matsura, S.X. Liu, V.A. Tyurin, J. Jianfei, F.B. Serinkan, and V.E. Kagan. 2003. Macrophage recognition of externalized phosphatidylserine and phagocytosis of apoptotic Jurkat cellsexistence of a threshold. <i>Arch. Biochem. Biophys.</i> 413:41-52.
	A9	Brand, M.D. 1995. Measurement of mitochondrial proton motive force. In Bioenergetics, a Practical Approach, Brown, G.C. and Cooper, C.E., editors, Oxford University Press, Oxford. 39-62.
	A10	Dubernard, J.M., E. Owen, G. Herzberg, M. Lanzetta, X. Martin, H. Kapila, M. Dawahra, and N.S. Hakim. 1999a. Human hand allograft: report on first 6 months. <i>Lancet</i> . 353:1315-1320.
	A11	Fadok, V.A., A. de Cathelineau, D.L. Daleke, P.M. Henson, and D.L. Bratton. 2001. Loss of phospholipid asymmetry and surface exposure of phosphatidylserine is required for phagocytosis of apoptotic cells by macrophages and fibroblasts. <i>J.Biol. Chem.</i> 276:1071-1077.
	A12	Fernandez-Botran, R., V. Gorantla, X. Sun, X. Ren, G. Perez-Abadia, F.A. Crespo, R. Oliver, H.I.Orhun, E.E. Quan, C. Maldonado, M. Ray, and J.H. Barker. 2002. Targeting of glycosaminoglycan-cytokine interactions as a novel therapeutic approach in allotransplantation. <i>Transplantation</i> . 74:623-629.
	A13	Francois, C.G., W.C. Breidenbach, C. Maldonado, T.P. Kakoulidis, A. Hodges, J.M. Dubernard, E. Owen, G.X. Pei, X.P. Ren, and J.H. Barker. 2000. Hand transplantation: Comparisons and observations of the first four clinical cases. <i>Microsurgery</i> . 20:360-371.

Examiner	Date Considered

	A34	Lenardo, M., K.M. Chan, F. Hornung, H. McFarland, R. Siegel, J. Wang, and L. Zheng. 1999. Mature T lymphocyte apoptosisimmune regulation in a dynamic and unpredictable
		antigenic environment. Annu.Rev.Immunol. 17:221-253.
	A35	Levine, B.L., W.B. Bernstein, N.E. Aronson, K. Schlienger, J. Cotte, S. Perfetto, M.J.
		Humphries, S. Ratto-Kim, D.L. Birx, C. Steffens, A. Landay, R.G. Carroll, and C.H. June. 2002. Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T
		cells and decreased CCR5 expression in HIV infection. <i>Nat Med.</i> 8:47-53.
	A36	Li, X.K., T. Okuyama, A. Tamura, S. Enosawa, Y. Kaneda, S. Takahara, N. Funashima, M.
	1 ^30	Yamada, H. Amemiya, and S. Suzuki. 1998. Prolonged survival of rat liver allografts
		transfected with Fas ligand-expressing plasmid. Transplantation. 66:1416-1423
	A37	Matsue, H., K. Matsue, M. Walters, K. Okumura, H. Yagita, and A. Takashima. 1999.
	1	Induction of antigen-specific immunosuppression by CD95L cDNA-transfected 'killer'
		dendritic cells, Nat. Med. 5:930-937.
	A38	Murray, J.E., J.P. Merrill, and J.H. Harrison. 1956. Renal homotransplantation in identical
		twins. Surg Forum 6:432-436.
	A39	Nagata, S., and P. Golstein. 1995. The Fas death factor. Science. 267:1449-1456.
	A40	Pahler, A., W.A. Hendrickson, M.A. Kolks, C.E. Argarana, and C.R. Cantor. 1987.
	1,110	Characterization and crystallization of core streptavidin. J Biol Chem. 262:13933-7.
	A41	Rivnay, B., E.A. Bayer, and M. Wilchek. 1987. Use of avidin-biotin technology for
		liposome targeting. Methods Enzymol. 149:119-23.
	A42	Salama, A.D., G. Remuzzi, W.E. Harmon, and M.H. Sayegh. 2001. Challenges to achieving .
· · · · · · · · · · · · · · · · · · ·		clinical transplantation tolerance. J.Clin.Invest. 108:943-948.
	A43	Sayegh, M.H. 1999. Finally, CTLA4Ig graduates to the clinic. <i>J.Clin.Invest.</i> 103:1223-1225.
	A44	Sayegh, M.H., and L.A. Turka. 1998. The role of T-cell costimulatory activation pathways
		in transplant rejection. N. Engl. J. Med. 338:1813-1821.
	A45	Schneider, P., N. Holler, J.L. Bodmer, M. Hahne, K. Frei, A. Fontana, and J. Tschopp. 1998.
		Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with
		downregulation of its proapoptotic activity and loss of liver toxicity. J.Exp.Med. 187:1205-
	1.10	1213. Shirwan, H., L. Barwari, and D.V. Cramer. 1997. Rejection of cardiac allografts by T cells
	A46	expressing a restricted repertoire of T-cell receptor V beta genes. <i>Immunology</i> . 90:572-578.
	A47	Suda, T., T. Takahashi, P. Golstein, and S. Nagata. 1993. Molecular cloning and expression
	A47	of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 75:1169-1178.
•	A48	Swenson, K.M., B. Ke, T. Wang, J.S. Markowitz, M.A. Maggard, G.S. Spear, D.K.
	1,740	lmagawa, J.A. Goss, R.W. Busuttil, and P. Seu. 1998. Fas ligand gene transfer to renal
		allografts in rats: effects on allograft survival. Transplantation. 65:155-160.
	A49	Sykes, M. 2001. Mixed chimerism and transplant tolerance. <i>Immunity</i> . 14:417-424.
	450	Sykes, M., and D.H. Sachs. 1990. Bone marrow transplantation as a means of inducing
	A50	tolerance. Semin.Immunol. 2:401-417.
		tolerance. Semin, immunoi. 2.401-417.
	A51	Takeuchi, T., T. Ueki, H. Nishimatsu, T. Kajiwara, T. Ishida, K. Jishage, 0. Ueda, H.
		Suzuki, B. Li, N. Moriyama, and T. Kitamura. 1999. Accelerated rejection of Fas ligand-
		expressing heart grafts. J Immunol. 162:518-522.
	A52	Thomas, J.M., D.M. Neville, J,L. Contreras, D.E. Eckhoff, G. Meng, A.L. Lobashevsky,
		P.X. Wang, Z.Q. Huang, K.M. Verbanac, C.E. Haisch, and F.T. Thomas. 1997. Preclinical
		studies of allograft tolerance in rhesus monkeys: a novel anti-CD3-immunotoxin given
		peritransplant with donor bone marrow induces operational tolerance to kidney allografts.
		Transplantation. 64:124-135.
	A53	Thompson, L.D., and P.C. Weber. 1993. Construction and expression of a synthetic streptavidin-encoding gene in Escherichia coli. <i>Gene.</i> 136:243-6.
		Sucplayium-chooding gene in Escherichia con. Gene. 150.245-0.
	1	

A54	Tilney, N. 1996. Transplantation and Transplantation Biology: From legend to reality. In Transplantation Biology: Cellular and Molecular Aspects. N. Tilney, T. Seam, and L. Paul, editors. Lippincott-Raven, Philadelphia, PA. 1-10.
A55	Van Parijs, L., and A.K. Abbas. 1998. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. <i>Science</i> . 280:243-248.
A56	von Andrian, U.H. 2002. Immunology. T cell activation in six dimensions. <i>Science</i> . 296:1815-7.
A57	Waldmann, H. 2002. A personal history of the CAMPATH-1 H antibody. <i>Med. Oncol.</i> 19 Suppl:S3-S9.
A58	Wekerle, T., J. Kurtz, H. Ito, J.V. Ronquillo, V. Dong, G. Zhao, J. Shaffer, M.H. Sayegh, and M. Sykes. 2000. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat !vied. 6:464-469.
A59	Wekerle, T., M.H. Sayegh, J. Hill, Y. Zhao, A. Chandraker, K.G. Swenson, G. Zhao, and M. Sykes. 1998. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J.Exp. Med. 187:2037-2044.
A60	Yolcu, E.S., N. Askenasy, N.P. Singh, S.E. Cherradi, and H. Shirwan. 2002. Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity. 17:795-808.
A61	Zhang, H., Y. Yang, J.L. Horton, E.B. Samoilova, T.A. Judge, L.A. Turka, J.M. Wilson, and Y. Chen. 1997. Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. <i>J.Clin.Invest.</i> 100:1951-1957.
A62	Zhang, H.G., X. Su, D. Liu, W. Liu, P. Yang, Z. Wang, C.K. Edwards, H. Bluethmann, J.D. Mountz, and T. Zhou. 1999. Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells. <i>J,Immunol.</i> 162:1423-1430.